- Director, Biologic Therapeutics Center
- BA, Chemistry: West Georgia College, Carrollton, GA (1978)
- MD: Emory University School of Medicine, Atlanta, GA (1982)
- Internship: Emory University, Atlanta, GA (1983)
- Residency, Medicine: Emory University, Atlanta, GA (1985)
- Fellowship, Pulmonary Medicine: National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (1989)
- Fellowship, Biotechnology: Navy Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD (1990)
- PhD, Virology: Groningen University, Groningen, The Netherlands (2002)
- Diplomat, American Board of Internal Medicine (1987)
- Certificate of Recognition: Research Affairs Committee, Washington University School of Medicine (2015)
- Director, Division of Cancer Biology: Department of Radiation Oncology, Washington University School of Medicine (2011-2016)
David T. Curiel, MD, PhD, is a tenured professor in the Cancer Biology Division of the Department of Radiation Oncology. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011 and is the Director of the Biologic Therapeutics Center. His work is focused on gene transfer vectors to advance the human application of gene therapy, virotherapy, and vaccinology. His oncolytic virotherapy for glioblastoma is fast track for FDA approval. He is also the editor in chief for the Journal of Ovarian Research. Currently he is a funded member of the NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program.
Human gene therapy offers unprecedented opportunities to achieve targeted therapy for a range of inherited and acquired disorders. Recent human trials have achieved spectacular cures in contexts whereby available gene transfer vectors could address the central mandate of effective gene delivery. Field advancements for gene therapy will thus clearly be linked to the development of vectors capable of efficient and specific gene delivery to target cells.
We are addressing these key issues via the employment of human adenovirus (Ad) as a vector vehicle. Genetic engineering of recombinant Ad has allowed dramatic gains in vector efficacy. Validation of vector gains in stringent model systems has allowed the translation of our novel Ad vectors into the context of pivotal human trials for a range of inherited and acquired disorders.
We are also exploring the utilities of gene editing to facilitate long term gene expression via adenoviral vectors. This new vector capacity now allows us to apply Ad for the wider context of corrective gene therapy for inherited genetic disease. Our work in this area is carried out via our membership within the NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program.
(Disclaimer: This listing may not include all articles associated with this person and may include publications related to others with a similar name.)